Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 1.00 |
| ▸ | PPARA | Q07869 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.50 |
| ▸ | FTH1 | P02794 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | TAS2R46 | P59540 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TERT | O14746 | 1/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Beta-Caryophyllene SCHEMBL4195147 | 1.00 | CNR2 (1.00) | CNR2PPARAMEN1KMT2ACYP3A4 | |
| Beta-Caryophyllene SCHEMBL3505514 | 1.00 | CNR2 (1.00) | CNR2PPARAMEN1KMT2ACYP3A4 | |
| Beta-Caryophyllene SCHEMBL113830 | 1.00 | CNR2 (1.00) | CNR2PPARAMEN1KMT2ACYP3A4 | |
| Caryophyllene SCHEMBL4355327 | 1.00 | CNR2 (1.00) | CNR2PPARAMEN1KMT2ACYP3A4 | |
| Beta-Caryophyllene SCHEMBL4195140 | 1.00 | CNR2 (1.00) | CNR2PPARAMEN1KMT2ACYP3A4 | |
| Beta-Caryophyllene SCHEMBL4195149 | 1.00 | CNR2 (1.00) | CNR2PPARAMEN1KMT2ACYP3A4 | |
| Beta-Caryophyllene SCHEMBL24774027 | 1.00 | CNR2 (1.00) | CNR2PPARAMEN1KMT2ACYP3A4 | |
| Beta-Caryophyllene SCHEMBL1866747 | 1.00 | CNR2 (1.00) | CNR2PPARAMEN1KMT2ACYP3A4 | |
| Beta-Caryophyllene SCHEMBL22607973 | 1.00 | CNR2 (1.00) | CNR2PPARAMEN1KMT2ACYP3A4 | |
| Beta-Caryophyllene SCHEMBL29380416 | 1.00 | CNR2 (1.00) | CNR2PPARAMEN1KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 586 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12357604-B2 | Topical formulations of cannabinoids and use thereof in the treatment of pain | INMED PHARMACEUTICALS INC. (CA) | 2025-07-15 | — | — | US | claimed |
| WO-2025090929-A1 | APPARATUS, SYSTEMS, AND METHODS FOR DETECTING HYPOGLYCEMIA | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2025-05-01 | — | — | WO | claimed |
| CN-113573592-B | Coated mouth feel enhancer | 味之素株式会社 | 2025-04-18 | — | — | CN | claimed |
| CN-119667037-A | Method for separating and measuring borneol substances and related impurities by GC (gas chromatography) | 上海博悦生物科技有限公司 | 2025-03-21 | — | — | CN | claimed |
| US-20250012013-A1 | Kombucha Cellulose-based Derivative Refined from a Symbiotic Colony of Bacteria and Yeast | KOMBUCHA BIOMATERIALS LLC | 2025-01-09 | — | — | US | claimed |
| US-12083156-B1 | Extracts derived from laser-irradiated rhizome of curcuma longa having enhanced antimicrobial activity | King Faisal University (SA) | 2024-09-10 | — | — | US | claimed |
| US-12042479-B2 | Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders | INMED PHARMACEUTICALS INC. | 2024-07-23 | — | — | US | claimed |
| US-11903990-B2 | Compositions and methods for treating and removing seborrheic keratoses | STOECKER WILLIAM VAN DOVER (US) | 2024-02-20 | — | — | US | claimed |
| EP-4257663-A1 | FOOD CONTACT SURFACE SANITIZING LIQUID | The Procter & Gamble Company (US) | 2023-10-11 | — | — | EP | claimed |
| US-20230302026-A1 | IMMUNOMODULATION FORMULATIONS AND RELATED METHODS | VICKERS ALEXANDER (US) | 2023-09-28 | — | — | US | claimed |
| US-20100166896-A1 | METHODS FOR REPELLING INSECTS USING SESQUITERPENE HYDROCARBONS AND THEIR DERIVATIVES | STERLING INTERNATIONAL INC. (US) | 2010-07-01 | — | — | US | claimed |
| EP-2162128-A1 | SESQUITERPENE FORMULATIONS, KITS AND METHODS OF USE THEREOF | F.p.l. Pharma Inc. (CA) | 2010-03-17 | — | — | EP | claimed |
| US-20090197949-A1 | ANTITUMOR METHODS AND COMPOSITIONS COMPRISING SESQUITERPENE DERIVATIVES | F.P.L. PHARMA, INC. (CA) | 2009-08-06 | — | — | US | claimed |
| WO-2008144942-A1 | SESQUITERPENE FORMULATIONS, KITS AND METHODS OF USE THEREOF | F.P.L. PHARMA INC. (CA) | 2008-12-04 | — | — | WO | claimed |
| EP-1372677-B1 | USE OF COMPOSITIONS COMPRISING SESQUITERPENE DERIVATIVES FOR THE TREATMENT OF CANCER | F P L PHARMA INC (CA) | 2008-04-30 | — | — | EP | claimed |
| US-20040247669-A1 | Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth | BENNES, INC. | 2004-12-09 | — | — | US | claimed |
| US-20040191342-A1 | Antitumor methods and compositions comprising sesquiterpene derivatives | F.P.L. PHARMA INC. (CA) | 2004-09-30 | — | — | US | claimed |
| US-20040151771-A1 | Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth | BENNES, INC. | 2004-08-05 | — | — | US | claimed |
| EP-1372677-A1 | ANTITUMOR METHODS AND COMPOSITIONS COMPRISING SESQUITERPENE DERIVATIVES | F.P.L. Pharma Inc. (CA) | 2004-01-02 | — | — | EP | claimed |
| WO-2002078719-A1 | ANTITUMOR METHODS AND COMPOSITIONS COMPRISING SESQUITERPENE DERIVATIVES | F.P.L. PHARMA INC. (CA) | 2002-10-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100166896-A1 | METHODS FOR REPELLING INSECTS USING SESQUITERPENE HYDROCARBONS AND THEIR DERIVATIVES | CYP51A1, LSS, DAGLA | CNR2 425/4885PPARA 1267/4885MEN1 3334/4885 |
| US-12357604-B2 | Topical formulations of cannabinoids and use thereof in the treatment of pain | CNR2, CNR1, LCAT | CNR2 1/4885PPARA 46/4885MEN1 4039/4885 |
| US-11903990-B2 | Compositions and methods for treating and removing seborrheic keratoses | CAT, CUTA, GPX1 | CNR2 4467/4885PPARA 1261/4885MEN1 3487/4885 |
| US-12042479-B2 | Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders | KRT18, DSP, DSC1 | CNR2 28/4885PPARA 1391/4885MEN1 2431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.